Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Mesoblast LimitedNASDAQ: MESO

Depreciation & Amortization · Q4 FY2026 · quarter ended Jun 2026

Depreciation & amortization dips below year-ago levels

Q4 FY2026 depreciation & amortization of $1.5M fell 6.1% year over year, behind the +46.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +28.1% a year.

Context

  • Depreciation & amortization amounted to 7.1% of revenue in FY2026, down 30.1 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.1% toward the trailing-twelve-month pace of +46.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.5M+0.0% QoQ
Last fiscal yearJun 2026
$8.62M+34.7% YoY
LTMJun 2026
$6.25M+46.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.1%——
1 year+34.7%——
3-year CAGR+28.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2026
8.62M USD
Year-over-year change
+34.7%
4-year CAGR
+18.5%

Depreciation & Amortization vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 depreciation & amortization of $6.25M is the 5th highest of the 6 companies compared; the peer median is $12.49M.
  • Its year-over-year change of +46.6% is the 3rd highest of 6, against a peer median of +20.9%.
  • Depreciation & amortization amounts to 5.2% of revenue for MESO, versus a peer median of 16.3%.
MESO Competitors Peer median
Depreciation & Amortization for MESO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1B +66925.2%+52.5%—
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M +111.9%+16.3%3.7%
FATEFate Therapeutics, Inc.LTM Mar 2026$12.49M -28.5%-12.3%197.7%
CELUCelularity Inc.LTM Dec 2025$7.34M -7.4%-8.2%27.6%
MESOMesoblast LimitedLTM Jun 2026$6.25M +46.6%+28.1%5.2%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$723K +20.9%-1.3%4.9%
Peer median (excluding MESO) $12.49M+20.9%-1.3%16.3%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.